Loading...
Docoh

Macrogenics (MGNX)

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

MGNX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
11 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.47M 21.47M 21.47M 21.47M 21.47M 21.47M
Cash burn (monthly) 8.62M 13.96M 13.94M 18.31M 16.39M 14.66M
Cash used (since last report) 12.08M 19.57M 19.54M 25.66M 22.97M 20.55M
Cash remaining 9.39M 1.9M 1.93M -4.19M -1.5M 914.08K
Runway (months of cash) 1.1 0.1 0.1 -0.2 -0.1 0.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 22 Karrels James Common Stock Buy Acquire P No No 2.47 40,000 98.8K 191,776
23 May 22 William K Heiden Stock Option Common Stock Grant Acquire A No No 3.96 36,000 142.56K 36,000
19 May 22 Siegel Jay Philip Stock Option Common Stock Grant Acquire A No No 3.9 24,080 93.91K 24,080
19 May 22 Siegel Jay Philip Stock Option Common Stock Grant Acquire A No No 3.9 18,000 70.2K 18,000
19 May 22 O'Brien Federica F. Stock Option Common Stock Grant Acquire A No No 3.9 24,080 93.91K 24,080
19 May 22 O'Brien Federica F. Stock Option Common Stock Grant Acquire A No No 3.9 18,000 70.2K 18,000
13F holders Current Prev Q Change
Total holders 146 158 -7.6%
Opened positions 19 25 -24.0%
Closed positions 31 22 +40.9%
Increased positions 58 53 +9.4%
Reduced positions 39 48 -18.8%
13F shares Current Prev Q Change
Total value 661.28M 2.32B -71.5%
Total shares 68.16M 65.05M +4.8%
Total puts 0 36.9K EXIT
Total calls 35.5K 46.2K -23.2%
Total put/call ratio 0.8
Largest owners Shares Value Change
BLVGF Bellevue 7.33M $64.54M -14.4%
BBBOF BB Biotech 7.28M $116.77M 0.0%
Ra Capital Management 6.1M $53.77M 0.0%
BLK Blackrock 5.17M $45.52M -0.5%
Armistice Capital 5M $44.05M +85.2%
Wasatch Advisors 4.04M $35.6M -1.6%
Vanguard 4.03M $35.52M +2.2%
RTW Investments 3.98M $35.03M 0.0%
STT State Street 3.54M $31.23M +21.7%
Perceptive Advisors 1.56M $13.74M -6.3%
Largest transactions Shares Bought/sold Change
Armistice Capital 5M +2.3M +85.2%
Point72 Asset Management 0 -1.26M EXIT
BLVGF Bellevue 7.33M -1.23M -14.4%
Assenagon Asset Management 1.25M +1.08M +618.9%
Great Point Partners 0 -1M EXIT
STT State Street 3.54M +632.05K +21.7%
Renaissance Technologies 585.71K +585.71K NEW
Millennium Management 1.52M +488.6K +47.5%
FMR 873.69K -376.79K -30.1%
MS Morgan Stanley 613.11K +367.15K +149.3%

Financial report summary

?
Risks
  • If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.
  • The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.
  • Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
  • Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.
Management Discussion
  • We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators. These product candidates include multiple immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accrual, add, adequate, adequately, administered, arise, armed, attain, attract, boxed, breach, civil, Cohort, competing, comprehensive, conclusion, confidence, confirm, contraindication, costly, country, coupled, criminal, decide, decided, deny, deteriorate, dilutive, diminished, discretion, dysfunction, efficacy, endpoint, energy, experienced, extreme, fail, field, final, force, gastric, halt, harm, head, health, higher, highly, identification, import, imposition, inability, inconclusive, inflation, instability, interrupt, IRB, judicially, larger, left, lengthy, line, macroeconomic, MAHOGANY, mandatory, manner, midst, morale, neck, overseeing, past, patient, pembrolizumab, permitted, personnel, pharmaceutical, preliminary, prescribing, prevent, prevented, progressed, prolonged, promising, promote, prospective, publicly, published, qualification, recession, recruitment, recurrent, refusal, rely, renegotiate, repeat, reputation, restructuring, resubmit, safety, satisfaction, saving, SCCHN, scientific, secondary, show, side, Similarly, size, slowdown, smaller, spending, stability, stopped, suffer, suffered, suitable, suspended, suspension, TAMARACK, terrorist, therapy, threatened, top, toxicity, turn, unacceptable, uncommitted, undergo, undergone, undesirable, unemployment, unexpected, unforeseen, unplanned, unrest, vary, ventricular, verification, voluntary, war, warning, widespread, wind, withdrawal
Removed: begin, expansion, exposure

Patents

Utility
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
12 Jul 22
The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”).
Utility
Combination Therapy for the Treatment of Cancer
30 Jun 22
The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation.
Utility
FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
9 Jun 22
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA.
Utility
Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
9 Jun 22
The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody (“margetuximab”), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable.
Utility
Methods and Compositions for Treatment of Lupus
26 May 22
Disclosed herein, in one aspect, is a method of treating B cell driven autoimmune and allergic diseases, such as lupus, comprising administering to a patient in need thereof an effective amount of B cell inhibitor that is non-depletional.